Healthcare Industry News: CoreValve
News Release - February 15, 2010
Stentys Drug-Eluting Self-Expanding Coronary Stent Shows 4% Restenosis in Complex LesionsLong-term follow-up data in Stentys DES and BMS clinical study shows superior results in the treatment of bifurcations
PRINCETON, N.J., and PARIS--(HSMN NewsFeed)--Medical device pioneer Stentys announced today that the complete ‘OPEN-I’ clinical study was presented by Stefan Verheye, M.D., Ph.D., at the Joint Interventional Meeting (“JIM”) 2010 in Rome, demonstrating superior results in 60 patients (27 Stentys drug-eluting stents and 33 Stentys bare-metal stents) who were followed–up angiographically after six months.
“These data fortify our conviction of the indisputable superiority of Stentys self-expanding and drug-eluting stents over balloon-expandable DES for the treatment of complex cases,” added Gonzague Issenmann, CEO and co-founder of Stentys. “We are actively pursuing our clinical program, particularly in the treatment of Acute Myocardial Infarction, to also prove the superiority of the Stentys technology in this additional group of patients.”
Based in Princeton, N.J., and Paris, Stentys intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. The Company announced in December 2009 that it has started enrolling patients in the randomized APPOSITION II clinical trial to compare the Stentys self-expanding stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth. Stentys was co-founded by Gonzague Issenmann and Jacques Séguin, M.D., Ph.D., founder of CoreValve, which was acquired last year by Medtronic for $700 million plus earn-outs.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.